AlphaStocks
4.6
Weak

Jazz Pharmaceuticals plc (JAZZ)

As of Sep 20, 2026, Jazz Pharmaceuticals plc (JAZZ) scores 4.6/10 on AlphaStocks' five-model composite, #126 of 168 Health Care stocks. At $241, JAZZ trades 56% above its model fair value of $154.

Health Care / Pharmaceuticals

S&P MidCap 400

$240.67

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#126out of 168 in Health Care

Is Jazz Pharmaceuticals plc a Good Investment in 2026?

Jazz Pharmaceuticals plc (JAZZ) scores 4.6 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates Jazz Pharmaceuticals plc as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield -2.3% · ROC -11%. Jazz Pharmaceuticals plc currently trades 56% above its estimated fair value of $154. Jazz Pharmaceuticals plc ranks #126 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-8.6Market Cap16B

Estimated Fair Value

$154.3556% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield -2.3% · ROC -11%

Frequently Asked Questions

Is Jazz Pharmaceuticals plc (JAZZ) a good investment?
As of Sep 20, 2026, Jazz Pharmaceuticals plc (JAZZ) scores 4.6/10 on AlphaStocks' five-model composite, #126 of 168 Health Care stocks. At $241, JAZZ trades 56% above its model fair value of $154. That score is below average, suggesting caution.
What is Jazz Pharmaceuticals plc's Piotroski F-Score?
Jazz Pharmaceuticals plc's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is JAZZ overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $154, JAZZ appears overvalued. The stock currently trades 56% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does JAZZ compare to other Health Care stocks?
Jazz Pharmaceuticals plc ranks #126 out of 168 stocks in the Health Care sector, placing it in the top 75% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about JAZZ?
AlphaStocks evaluates JAZZ using five proven investment models. Piotroski: Attractive; Buffett: Caution; Graham: Caution; Lynch: Attractive; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.6/10.

Similar Stocks

AMPHLLYACAD

Compare JAZZ with

AMPH vs JAZZJAZZ vs LLYACAD vs JAZZ

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer